一品红：子公司创新药APH03621片临床试验获批

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its innovative drug APH03621, which will soon commence clinical trials [1] Group 1: Drug Development - APH03621 is a new oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist (GnRH-ant) [1] - The drug is intended for the treatment of endometriosis [1]